Great DFS. Surely a great relief. Surely, an upgrade in rating. Wondering anybody other than Macquarie and Cannacord covering GXY ?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%